

IMPORTANT: Hong Kong Exchange and Clearing Limited (“**HKEx**”), The Stock Exchange of Hong Kong Limited (“**SEHK**”), the Securities and Futures Commission (“**SFC**”) and the Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this Announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Announcement.

The Manager accepts full responsibility for the accuracy of the information contained in this Announcement as at the date of publication, and confirms, having made all reasonable enquiries, that to the best of its knowledge and belief, as at the date of publication, opinions expressed in this Announcement have been arrived at after due and careful consideration.

SFC authorisation is not a recommendation or endorsement of a scheme nor does it guarantee the commercial merits of a scheme or its performance. It does not mean the scheme is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.

If you are in doubt about the contents of this Announcement, you should consult your stockbroker, bank manager, solicitor, accountant or other professional adviser.

ChinaAMC Hang Seng Hong Kong Biotech Index ETF

(the “Sub-Fund”)

*(A sub-fund of ChinaAMC Global ETF Series, a Hong Kong umbrella unit trust,
authorised under Section 104 of the Securities and Futures Ordinance
(Cap. 571) of Hong Kong)*

HKD Counter Stock Code: 03069
USD Counter Stock Code: 09069

Announcement – Unaudited Semi-annual Report 2022

China Asset Management (Hong Kong) Limited (the “**Manager**”) hereby announces that the unaudited semi-annual report of the Sub-Fund for the period ended 30 June 2022 (in English only) is now available. The electronic copy of the report can be obtained on the Manager’s website at www.chinaamc.com.hk¹ and HKEx’s website at www.hkex.com.hk from 16 August 2022. In addition, Investors may also visit the Manager’s office to obtain a hard copy of the report.

Investors who have any enquiries regarding the above may contact the Manager at 37th Floor, Bank of China Tower, 1 Garden Road, Central, Hong Kong or our enquiry hotline at (852) 3406 8686 during office hours.

China Asset Management (Hong Kong) Limited

Date: 16 August 2022

¹ This website has not been reviewed by SFC.